Indications / Non-small cell lung cancer · Breast cancer · Pancreatic cancer · Colorectal cancer · Acute myeloid leukemia · Chronic myeloid leukemia · Multiple myeloma · Glioblastoma · Glioma · Neuroblastoma · Medulloblastoma · Diffuse midline glioma (DIPG) · Ependymoma · Atypical teratoid rhabdoid tumour (AT/RT) · Childhood acute lymphoblastic leukemia · Ewing sarcoma · Osteosarcoma · Rhabdomyosarcoma
Chronic myeloid leukemia
Asciminib and the STAMP inhibitors, treatment-free remission and resistance after ponatinib.
Live from ClinicalTrials.gov, fetched 2026-11-11 15:17 UTC. Every row links to its source record.
Drug trials updated in the last 16 months
261
Phase 1 to 3, interventional
For relapsed or refractory disease
16%
41 trial titles name relapsed, refractory or recurrent disease
Led by industry
25%
66 trials with a company as lead sponsor
26 of the 261 chronic myeloid leukemia trials are Phase 3; 28 were stopped early
Drug trials in this cancer with a registry update in the last 16 months, by phase. Each bar is split by where the trial stands today.
Running or not yet startedCompletedStopped early (terminated, withdrawn or suspended)
A trial that spans two phases counts as the later one. Stopped early is the registry status, whatever the reason given. Source: ClinicalTrials.gov, fetched live.
Programs: each drug in each segment
A program is one drug in one segment of chronic myeloid leukemia (biomarker, line of therapy, setting), so the same drug can be Phase 3 in one segment and Phase 1 in another. Segments are read from each trial's title and conditions by published rules; 106 of 261 trials name no segment and are listed as Untagged.
Segment:All1L2L+2L+ · Relapsed or refractoryaccelerated phaseaccelerated phase · 1Laccelerated phase · 2L+ · Relapsed or refractoryaccelerated phase · Relapsed or refractoryAdvanced or metastaticBCR-ABLBCR-ABL · 1Lblast phaseblast phase · 1L · Relapsed or refractoryblast phase · Advanced or metastaticblast phase · Relapsed or refractorychronic phasechronic phase · 1Lchronic phase · 2L+chronic phase · 2L+ · Relapsed or refractorychronic phase · Relapsed or refractoryMaintenanceRelapsed or refractoryT315IUntagged
| Drug | Segment | Modality | Highest phase | Trials |
|---|---|---|---|---|
| cyclophosphamide National Cancer Institute (NCI) | Untagged | Small molecule | Ph3 | NCT06904066, NCT06013423, NCT05364762, NCT03779854 +21 |
| Fludarabine M.D. Anderson Cancer Center | Untagged | Other or not recognised | Ph3 | NCT07604233, NCT03779854, NCT03849651, NCT07819396 +11 |
| tacrolimus City of Hope Medical Center | Untagged | Other or not recognised | Ph3 | NCT01885689, NCT05364762, NCT03779854, NCT05807932 +10 |
| Azacitidine Taiho Oncology, Inc. | Untagged | Other or not recognised | Ph2/Ph3 | NCT04256317, NCT04256317, NCT05201066, NCT03588078 +8 |
| Venetoclax M.D. Anderson Cancer Center | Untagged | Small molecule | Ph2/Ph3 | NCT07604233, NCT04256317, NCT05768711, NCT05201066 +8 |
| Mycophenolate Mofetil Fred Hutchinson Cancer Center | Relapsed or refractory | Other or not recognised | Ph3 | NCT04375631, NCT02861417, NCT05805605, NCT03128034 +6 |
| Busulfan Fred Hutchinson Cancer Center | Untagged | Other or not recognised | Ph2/Ph3 | NCT03779854, NCT06001385, NCT04708054, NCT01135329 +3 |
| Fludarabine Phosphate City of Hope Medical Center | Relapsed or refractory | Other or not recognised | Ph3 | NCT07582172, NCT05092451, NCT02861417, NCT03128034 +3 |
| Thiotepa Fred Hutchinson Cancer Center | Untagged | Other or not recognised | Ph2/Ph3 | NCT06013423, NCT03779854, NCT03849651, NCT06680661 +2 |
| azacitidine Sellas Life Sciences Group | 1L | Other or not recognised | Ph3 | NCT04588922, NCT03862157, NCT06647862, NCT03268954 +1 |
| Cyclosporine Fred Hutchinson Cancer Center | Relapsed or refractory | Other or not recognised | Ph3 | NCT04375631, NCT03128034, NCT04195633, NCT03246906 +1 |
| fludarabine phosphate National Cancer Institute (NCI) | Untagged | Other or not recognised | Ph2/Ph3 | NCT06904066, NCT06013423, NCT04708054, NCT03192397 +1 |
| Asciminib M.D. Anderson Cancer Center | Untagged | Small molecule | Ph3 | NCT07604233, NCT03874858, NCT05413915, NCT04216563 |
| Sirolimus City of Hope Medical Center | Relapsed or refractory | Other or not recognised | Ph3 | NCT07582172, NCT03246906, NCT01231412, NCT02790515 |
| Venetoclax M.D. Anderson Cancer Center | 1L | Small molecule | Ph3 | NCT04655755, NCT04588922, NCT03862157, NCT07082452 |
| ABL001 Novartis Pharmaceuticals | Untagged | Other or not recognised | Ph3 | NCT04948333, NCT04948333, NCT04948333 |
| Asciminib M.D. Anderson Cancer Center | chronic phase · 1L | Small molecule | Ph3 | NCT06236724, NCT05456191, NCT03906292 |
| Dasatinib Jiangsu Hansoh Pharmaceutical Co., Ltd. | 1L | Small molecule | Ph3 | NCT07885293, NCT07804901, NCT04971226 |
| G-csf St. Jude Children's Research Hospital | Untagged | Other or not recognised | Ph3 | NCT03849651, NCT03480360, NCT02793544 |
| Imatinib Il-Yang Pharm. Co., Ltd. | chronic phase | Small molecule | Ph3 | NCT03722420, NCT03654768, NCT04070443 |
| ASTX030 Taiho Oncology, Inc. | Untagged | Other or not recognised | Ph2/Ph3 | NCT04256317, NCT04256317 |
| Bosutinib Ascentage Pharma Group Inc. | chronic phase | Small molecule | Ph3 | NCT06423911, NCT03654768 |
| Imatinib Jiangsu Hansoh Pharmaceutical Co., Ltd. | 1L | Small molecule | Ph3 | NCT07885293, NCT04971226 |
| Imatinib Obafemi Awolowo University | Untagged | Small molecule | Ph3 | NCT07022743, NCT05413915 |
| Lenalidomide National Cancer Institute (NCI) | Untagged | Small molecule | Ph3 | NCT00843882, NCT01522976 |
| Nilotinib Jiangsu Hansoh Pharmaceutical Co., Ltd. | 1L | Small molecule | Ph3 | NCT07885293, NCT04971226 |
| Nilotinib Novartis Pharmaceuticals | chronic phase · 1L | Small molecule | Ph3 | NCT05456191, NCT03906292 |
| olverembatinib M.D. Anderson Cancer Center | chronic phase | Small molecule | Ph3 | NCT06817720, NCT06423911 |
| Pevonedistat M.D. Anderson Cancer Center | 1L | Small molecule | Ph3 | NCT03862157, NCT03268954 |
| sabatolimab Novartis Pharmaceuticals | Untagged | Antibody | Ph3 | NCT05201066, NCT04266301 |
| ABL001 Novartis Pharmaceuticals | chronic phase | Other or not recognised | Ph3 | NCT04666259 |
| Asciminib Novartis Pharmaceuticals | 1L | Small molecule | Ph3 | NCT04971226 |
| Asciminib Novartis Pharmaceuticals | 2L+ | Small molecule | Ph3 | NCT03106779 |
| Bosutinib Novartis Pharmaceuticals | 1L | Small molecule | Ph3 | NCT04971226 |
| Bosutinib Novartis Pharmaceuticals | 2L+ | Small molecule | Ph3 | NCT03106779 |
| Cedazuridine Taiho Oncology, Inc. | Untagged | Other or not recognised | Ph2/Ph3 | NCT04256317 |
| cellcept Dartmouth-Hitchcock Medical Center | Untagged | Other or not recognised | Ph3 | NCT03480360 |
| Cladribine M.D. Anderson Cancer Center | Untagged | Other or not recognised | Ph2/Ph3 | NCT04708054 |
| ELVN-001 Enliven Therapeutics | chronic phase · 2L+ | Other or not recognised | Ph3 | NCT07905183 |
| Epoetin Alfa National Cancer Institute (NCI) | Untagged | Other or not recognised | Ph3 | NCT00843882 |
| Flumatinib Jiangsu Hansoh Pharmaceutical Co., Ltd. | 1L | Small molecule | Ph3 | NCT07885293 |
| HS-10382 Jiangsu Hansoh Pharmaceutical Co., Ltd. | 1L | Other or not recognised | Ph3 | NCT07885293 |
| IMM01 ImmuneOnco Biopharmaceuticals (Shanghai) Inc. | 1L | Other or not recognised | Ph3 | NCT06647862 |
| NiCord® Gamida Cell ltd | Untagged | Other or not recognised | Ph3 | NCT02730299 |
| Nilotinib (Tasigna ®) and Pegylated interferon alfa 2a Hospices Civils de Lyon | chronic phase · 1L | Small molecule | Ph3 | NCT02201459 |
| Nilotinib (Tasigna ®), capsules of Hospices Civils de Lyon | chronic phase · 1L | Small molecule | Ph3 | NCT02201459 |
| Radotinib Il-Yang Pharm. Co., Ltd. | chronic phase | Small molecule | Ph3 | NCT03722420 |
| Radotinib HCl Il-Yang Pharm. Co., Ltd. | chronic phase · Relapsed or refractory | Small molecule | Ph3 | NCT03459534 |
| TGRX-678 Shenzhen TargetRx Co., Ltd. | chronic phase | Other or not recognised | Ph3 | NCT07489755 |
| TKI Enliven Therapeutics | chronic phase · 2L+ | Other or not recognised | Ph3 | NCT07905183 |
| TKI Shenzhen TargetRx Co., Ltd. | chronic phase | Other or not recognised | Ph3 | NCT07489755 |
| treatment of TKI in CML Poitiers University Hospital | Untagged | Other or not recognised | Ph3 | NCT05753384 |
| Mycophenolate Mofetil Fred Hutchinson Cancer Center | Untagged | Other or not recognised | Ph2 | NCT06013423, NCT05807932, NCT06680661, NCT06001385 +8 |
| Azacitidine Uma Borate | Relapsed or refractory | Other or not recognised | Ph1/Ph2 | NCT06523556, NCT01892371, NCT04140487, NCT04493138 +7 |
| Cyclophosphamide Fred Hutchinson Cancer Center | Relapsed or refractory | Small molecule | Ph1/Ph2 | NCT04375631, NCT05092451, NCT02861417, NCT05805605 +6 |
| Fludarabine Fred Hutchinson Cancer Center | Relapsed or refractory | Other or not recognised | Ph2 | NCT04375631, NCT02861417, NCT05805605, NCT04195633 +4 |
| melphalan City of Hope Medical Center | Untagged | Other or not recognised | Ph2 | NCT01885689, NCT03849651, NCT06001385, NCT06815003 +4 |
| Venetoclax M.D. Anderson Cancer Center | Relapsed or refractory | Small molecule | Ph1/Ph2 | NCT04140487, NCT04550442, NCT05428969, NCT06563804 +4 |
| Tacrolimus City of Hope Medical Center | Relapsed or refractory | Other or not recognised | Ph2 | NCT07582172, NCT02861417, NCT03670966, NCT03674411 +2 |
| Cytarabine M.D. Anderson Cancer Center | Relapsed or refractory | Other or not recognised | Ph1/Ph2 | NCT01892371, NCT03418038, NCT04375631, NCT04375631 +1 |
Showing the 60 most advanced of 434 programs.
Assets over time
261 trials updated in the last 16 months. Each row is an asset; each dot is one of its trials at first posting, sized by phase. Orange is Phase 3.
| Asset | Lead sponsor | |
|---|---|---|
| Azacitidine | M.D. Anderson Cancer Center | |
| Cyclophosphamide | Fred Hutchinson Cancer Center | |
| asciminib | Thomas Ernst, Prof. Dr. med. | |
| Venetoclax | Groupe Francophone des Myelodysplasies | |
| Busulfan | Center for International Blood and Marrow Transplant Research | |
| Imatinib | Obafemi Awolowo University | |
| ABL001 | Novartis Pharmaceuticals | |
| ELVN-001 | Enliven Therapeutics | |
| TGRX-678 | Shenzhen TargetRx Co., Ltd. | |
| olverembatinib | M.D. Anderson Cancer Center | |
| Cyclosporine | Fred Hutchinson Cancer Center | |
| HS-10382 | Jiangsu Hansoh Pharmaceutical Co., Ltd. | |
| Epoetin Alfa | National Cancer Institute (NCI) | |
| Radotinib | Il-Yang Pharm. Co., Ltd. | |
| Radotinib HCl | Il-Yang Pharm. Co., Ltd. | |
| treatment of TKI in CML | Poitiers University Hospital | |
| NiCord® | Gamida Cell ltd | |
| Sabatolimab | Novartis Pharmaceuticals | |
| IMM01 | ImmuneOnco Biopharmaceuticals (Shanghai) Inc. | |
| Nilotinib (Tasigna ®), capsules of | Hospices Civils de Lyon | |
| Dasatinib | M.D. Anderson Cancer Center | |
| Fludarabine | M.D. Anderson Cancer Center | |
| Ponatinib | Otsuka Beijing Research Institute | |
| Decitabine | M.D. Anderson Cancer Center | |
| Ruxolitinib | Hannah Choe, MD | |
| nilotinib | Novartis Pharmaceuticals | |
| Cladribine | M.D. Anderson Cancer Center | |
| Olutasidenib | City of Hope Medical Center | |
| Blinatumomab | M.D. Anderson Cancer Center | |
| Axatilimab | Uma Borate |
All trials
Site countries come from each record's listed locations. Site counts are not patients per country, and trials registered only outside ClinicalTrials.gov are not covered.
| Trial | Phase | Sponsor | Status | Posted | Primary completion |
|---|---|---|---|---|---|
| ENABLE-2 · NCT07905183 A Randomized Study of ELVN-001 Versus Investigator-Selected TKI, in CP-CML Previously Treated With One or More TKIs No sites listed Decision brief → | Ph3 | Enliven Therapeutics | not yet recruiting | 2026-10-29 | 2028-12-31 |
| NCT07885293 A Study of HS-10382 Versus Investigator-selected TKIs in Adult Patients With Newly Diagnosed Ph+ CML-CP Single-country: China (1 site) Decision brief → | Ph3 | Jiangsu Hansoh Pharmaceutical Co., Ltd. | not yet recruiting | 2026-10-21 | 2029-07 |
| NCT07489755 TGRX-678 Chinese Phase III in Chronic Myelogenous Leukemia (CML) Patients No sites listed Decision brief → | Ph3 | Shenzhen TargetRx Co., Ltd. | not yet recruiting | 2026-03-24 | 2030-05-01 |
| SEVENAZA · NCT07082452 A Multicenter Trial Evaluating Efficacy and Safety of A Reduced Venetoclax Exposure To Seven Days Versus Standard Continuous Venetoclax Exposure Combined With Azacitidine in Treatment Naïve Subjects With Acute Myeloid Leukemia Who Are Ineligible for Intensive Induction Single-country: France (1 site) Decision brief → | Ph3 | Gustave Roussy, Cancer Campus, Grand Paris | not yet recruiting | 2025-07-24 | 2030-09 |
| NCT06647862 IMM01+Azacitidine VS Placebo +Azacitidine in Patients With Newly Diagnosed Chronic Myelomonocytic Leukemia (CMML1-2) Single-country: China (43 sites) Decision brief → | Ph3 | ImmuneOnco Biopharmaceuticals (Shanghai) Inc. | recruiting | 2024-10-18 | 2026-04-24 |
| POLARIS-2 · NCT06423911 Study of Olverembatinib (HQP1351) in Patients With CML-CP 16 countries, 31% of sites in the US Decision brief → | Ph3 | Ascentage Pharma Group Inc. | recruiting | 2024-05-21 | 2027-06-30 |
| NCT05753384 Discontinuation of TyrosIne Kinase Inhibitors (TKI) in Chronic Myeloid Leukemia (CML) and Impact on the Immune System Single-country: France (20 sites) Decision brief → | Ph3 | Poitiers University Hospital | active not recruiting | 2023-03-03 | 2028-12-01 |
| ASC4START · NCT05456191 A Study to Investigate Tolerability and Efficacy of Asciminib (Oral) Versus Nilotinib (Oral) in Adult Participants (≥18 Years of Age) With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia in Chronic Phase (Ph+ CML-CP) 24 countries, 8% of sites in the US Decision brief → | Ph3 | Novartis Pharmaceuticals | active not recruiting | 2022-07-13 | 2025-05-15 |
| NCT05413915 Asciminib Used in Consolidation With Imatinib vs. Imatinib to Achieve TFR in CP-CML Single-country: Canada (4 sites) Decision brief → | Ph3 | Sarit Assouline | terminated | 2022-06-10 | 2025-07-02 |
| NCT04971226 A Study of Oral Asciminib Versus Other TKIs in Adult Patients With Newly Diagnosed Ph+ CML-CP 29 countries, 12% of sites in the US Decision brief → | Ph3 | Novartis Pharmaceuticals | active not recruiting | 2021-07-21 | 2023-11-28 |
| NCT04948333 Asciminib Treatment Optimization in ≥ 3rd Line CML-CP 16 countries, 0% of sites in the US Decision brief → | Ph3 | Novartis Pharmaceuticals | completed | 2021-07-01 | 2024-03-12 |
| NCT04708054 Venetoclax to Improve Outcomes of Fractionated Busulfan Regimen in Patients With High-Risk AML and MDS Single-country: United States (1 site) Decision brief → | Ph2/Ph3 | M.D. Anderson Cancer Center | recruiting | 2021-01-13 | 2027-12-31 |
| AIM4CML · NCT04666259 Asciminib in Monotherapy for Chronic Myeloid Leukemia in Chronic Phase (CML-CP) With and Without T315I Mutation Single-country: United States (26 sites) Decision brief → | Ph3 | Novartis Pharmaceuticals | completed | 2020-12-14 | 2023-06-20 |
| STIMULUS-MDS2 · NCT04266301 Study of Efficacy and Safety of MBG453 in Combination With Azacitidine in Subjects With Intermediate, High or Very High Risk Myelodysplastic Syndrome (MDS) as Per IPSS-R, or Chronic Myelomonocytic Leukemia-2 (CMML-2) 36 countries, 7% of sites in the US Decision brief → | Ph3 | Novartis Pharmaceuticals | terminated | 2020-02-12 | 2024-10-02 |
| NCT04256317 A Multi-phase Study of ASTX030 (Azacitidine and Cedazuridine) in Myeloid Neoplasm Alone or in Combination With Venetoclax in AML (AZTOUND Study) 10 countries, 33% of sites in the US Decision brief → | Ph2/Ph3 | Taiho Oncology, Inc. | recruiting | 2020-02-05 | 2027-11-01 |
| NCT03844048 An Extension Study of Venetoclax for Subjects Who Have Completed a Prior Venetoclax Clinical Trial 23 countries, 13% of sites in the US Decision brief → | Ph3 | AbbVie | active not recruiting | 2019-02-18 | 2027-08 |
| NCT03722420 Randomized Evaluation of Radotinib Versus Imatinib in Phase III Study for Efficacy With Chinese Patients (RERISE China) Single-country: China (1 site) Decision brief → | Ph3 | Il-Yang Pharm. Co., Ltd. | active not recruiting | 2018-10-29 | 2023-03-03 |
| NCT03480360 Haploidentical Allogeneic Peripheral Blood Transplantation: Examining Checkpoint Immune Regulators' Expression Single-country: United States (1 site) Decision brief → | Ph3 | Dartmouth-Hitchcock Medical Center | completed | 2018-03-29 | 2025-02-14 |
| NCT03459534 A Phase 3 Study for the Efficacy and Safety of Radotinib in CP-CML Patients With Failure or Intolerance to Previous TKIs 4 countries, 0% of sites in the US Decision brief → | Ph3 | Il-Yang Pharm. Co., Ltd. | recruiting | 2018-03-09 | 2027-06-30 |
| PANTHER · NCT03268954 Pevonedistat Plus Azacitidine Versus Single-Agent Azacitidine as First-Line Treatment for Participants With Higher-Risk Myelodysplastic Syndromes (HR MDS), Chronic Myelomonocytic Leukemia (CMML), or Low-Blast Acute Myelogenous Leukemia (AML) 20 countries, 53% of sites in the US Decision brief → | Ph3 | Takeda | completed | 2017-08-31 | 2021-05-28 |
| NCT03106779 Study of Efficacy of CML-CP Patients Treated With ABL001 Versus Bosutinib, Previously Treated With 2 or More TKIs 25 countries, 11% of sites in the US Decision brief → | Ph3 | Novartis Pharmaceuticals | completed | 2017-04-10 | 2020-05-25 |
| NCT02730299 Stem Cell Transplantation With NiCord® (Omidubicel) vs Standard UCB in Patients With Leukemia, Lymphoma, and MDS 10 countries, 40% of sites in the US Decision brief → | Ph3 | Gamida Cell ltd | completed | 2016-04-06 | 2021-04-29 |
| PETALs · NCT02201459 Nilotinib ± Peg-IFN for First Line Chronic Phase CML Patients Single-country: France (1 site) Decision brief → | Ph3 | Hospices Civils de Lyon | completed | 2014-07-28 | 2022-10 |
| FLUBUTBI · NCT01366612 Fludarabine and Busulfan vs. Fludarabine, Busulfan and Total Body Irradiation Single-country: United States (1 site) Decision brief → | Ph3 | Hackensack Meridian Health | terminated | 2011-06-06 | 2020-08-17 |
| NCT01231412 Graft-Versus-Host Disease Prophylaxis in Treating Patients With Hematologic Malignancies Undergoing Unrelated Donor Peripheral Blood Stem Cell Transplant 3 countries, 55% of sites in the US Decision brief → | Ph3 | Fred Hutchinson Cancer Center | completed | 2010-11-01 | 2016-10-08 |
| NCT00843882 Lenalidomide With or Without Epoetin Alfa in Treating Patients With Myelodysplastic Syndrome and Anemia Single-country: United States (507 sites) Decision brief → | Ph3 | National Cancer Institute (NCI) | active not recruiting | 2009-02-13 | 2019-07-08 |
| MPN-RC 127 · NCT07872709 Oral Tetrahydrouridine-Decitabine in Patients With Advanced Myeloproliferative Neoplasms Single-country: United States (1 site) Decision brief → | Ph2 | John Mascarenhas | not yet recruiting | 2026-10-14 | 2029-07 |
| NCT07819396 Depletion of CD45RA Positive Naive T Cells for the Prevention of Graft Versus Host Disease in Older Patients Undergoing Allogeneic Hematopoietic Cell Transplantation for Acute Leukemia or Myelodysplastic Syndrome Single-country: United States (1 site) Decision brief → | Ph2 | Fred Hutchinson Cancer Center | not yet recruiting | 2026-09-14 | 2031-06-01 |
| ARTIST · NCT07804901 Asciminib Frontline Risk Adapted Single-country: Germany (1 site) Decision brief → | Ph2 | Prof. Dr. med. Andreas Hochhaus | not yet recruiting | 2026-09-04 | 2030-12-31 |
| ESTIMATION · NCT07789574 Efficacy of Asciminib in Chronic Phase CML Patients With T315I Mutations Single-country: Germany (10 sites) Decision brief → | Ph2 | Thomas Ernst, Prof. Dr. med. | recruiting | 2026-08-27 | 2030-06-30 |
| NCT07719348 A Study to Evaluate S241656 Alone or in Combination in Participants With Selected Myeloid Malignancies No sites listed Decision brief → | Ph1/Ph2 | Servier | not yet recruiting | 2026-07-22 | 2027-11-01 |
| NCT07604233 Phase 1/2 FLAG-IDA, VEN and Asciminib in CML and Ph+ AML Single-country: United States (1 site) Decision brief → | Ph1/Ph2 | M.D. Anderson Cancer Center | not yet recruiting | 2026-05-22 | 2031-06-03 |
| NCT07582172 Total Marrow and Lymphoid Irradiation in Combination With Fludarabine and Melphalan as Conditioning for Allogeneic Peripheral Blood Stem Cell Hematopoietic Cell Transplant in Older Patients With Refractory and Relapsed Acute Myeloid Leukemia and High-risk Myelodysplastic Syndrome Single-country: United States (1 site) Decision brief → | Ph2 | City of Hope Medical Center | recruiting | 2026-05-12 | 2031-11-05 |
| NCT07538401 ASCiminib, With or Without Dasatinib Combination, as a 2nd-Line Therapy to ADVANCE the Treatment for Chronic Myelogenous Leukemia in Chronic Phase (ASC2ADVANCE) No sites listed Decision brief → | Ph2 | University Health Network, Toronto | not yet recruiting | 2026-04-20 | 2028-04-25 |
| ASIM-POST Ph+ · NCT07493408 Asciminib & Standard-of-Care Integration in Maintenance Therapy for POST Allogeneic Stem Cell Transplant (Allo-HSCT) of Patient With Ph+ B-ALL or Blastic Transformed CML Single-country: Hong Kong (1 site) Decision brief → | Ph2 | The University of Hong Kong | not yet recruiting | 2026-03-25 | 2035-12-31 |
| NCT07468916 Ropeginterferon Alfa-2b for the Treatment of Myelodysplastic Syndrome/Myeloproliferative Neoplasm Overlap Syndromes and Chronic Myelomonocytic Leukemia Single-country: United States (1 site) Decision brief → | Ph2 | Jonsson Comprehensive Cancer Center | not yet recruiting | 2026-03-13 | 2032-01-30 |
| NCT07354074 Study to Determine the Efficacy and Safety of Asciminib in Pediatric Patients With Ph+ CML-CP 17 countries, 13% of sites in the US Decision brief → | Ph2 | Novartis Pharmaceuticals | recruiting | 2026-01-21 | 2033-02-23 |
| NCT07269470 Phase II Study Assessing the Safety and Efficacy of Dasatinib in Combination With Ropeginterferon in Patients With Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase Single-country: United States (1 site) Decision brief → | Ph2 | M.D. Anderson Cancer Center | recruiting | 2025-12-08 | 2029-11-01 |
| NCT07259161 Modified Conditioning Regimen for CML-BP No sites listed Decision brief → | Ph2 | Institute of Hematology & Blood Diseases Hospital, China | not yet recruiting | 2025-12-02 | 2029-09-14 |
| NCT07249346 Dose-Expansion Study of Low Dose Post-Transplant Cyclophosphamide/Tacrolimus/Ruxolitinib for Graft-versus-Host Disease (GVHD) Prophylaxis in Myeloablative Allogeneic Peripheral Blood Stem Cell Transplantation Single-country: United States (3 sites) Decision brief → | Ph2 | Hannah Choe, MD | recruiting | 2025-11-25 | 2027-06-01 |
| APTBCy · NCT07238712 Optimization of Post-transplantation Benadamustine and Cyclophosphamide in Patients With High-risk Myeloid Malignancies and a Partially Mismatched Donor Single-country: Russia (1 site) Decision brief → | Ph2 | St. Petersburg State Pavlov Medical University | recruiting | 2025-11-20 | 2026-12-10 |
| NCT07128381 Phase I/II Clinical Trial of Axatilimab, a CSF1R Monoclonal Antibody, in Combination With Ruxolitinib as Therapy for Patients With Myelofibrosis (MF) and Chronic Myelomonocytic Leukemia (CMML) Single-country: United States (1 site) Decision brief → | Ph1/Ph2 | M.D. Anderson Cancer Center | recruiting | 2025-08-19 | 2031-07-31 |
| NCT07046078 Combination Chemotherapy (FLAG-Ida) Followed Immediately by Reduced-Intensity Total Body Radiation Therapy and Donor Hematopoietic Cell Transplant for the Treatment of Adults Age 60 and Older With Newly Diagnosed Adverse-Risk Acute Myeloid Leukemia or Other High-Grade Myeloid Cancer Single-country: United States (1 site) Decision brief → | Ph2 | Fred Hutchinson Cancer Center | recruiting | 2025-07-01 | 2027-06-30 |
| PROSPERA · NCT07033598 Pacritinib vs. Hydroxyurea in Advanced Proliferative Chronic Myelomonocytic Leukemia 2 countries, 67% of sites in the US Decision brief → | Ph2 | Theradex | recruiting | 2025-06-24 | 2028-07 |
| NCT07022743 Improving Treatment Outcomes in Chronic Myeloid Leukaemia Patients Using Imatinib and Artesunate Combination Therapy Single-country: Nigeria (1 site) Decision brief → | Ph2 | Obafemi Awolowo University | active not recruiting | 2025-06-15 | 2027-06 |
| NCT06928662 Chemotherapy (Decitabine in Combination With FLAG-Ida) and Total-Body Irradiation Followed by Donor Stem Cell Transplant for the Treatment of Adults With Myeloid Malignancies at High Risk of Relapse Single-country: United States (1 site) Decision brief → | Ph1/Ph2 | Fred Hutchinson Cancer Center | recruiting | 2025-04-15 | 2028-03-09 |
| ACCELERATE · NCT06859424 A Platform Protocol to Investigate Post-Transplant Cyclophosphamide-Based Graft-Versus-Host Disease Prophylaxis in Patients With Hematologic Malignancies Undergoing Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation Single-country: United States (13 sites) Decision brief → | Ph2 | Center for International Blood and Marrow Transplant Research | recruiting | 2025-03-05 | 2028-06 |
| NCT06817720 Phase II Study Assessing the Efficacy and Toxicity of Olverembatinib Monotherapy in Patients With Chronic Myeloid Leukemia in Chronic Phase After Failing One Prior Therapy With a Second Generation Tyrosine Kinase Inhibitor or Asciminib Single-country: United States (1 site) Decision brief → | Ph2 | M.D. Anderson Cancer Center | recruiting | 2025-02-10 | 2027-03-07 |
| NCT06815003 Vedolizumab Plus Post-transplant Cyclophosphamide and Short Course Tacrolimus for the Prevention of Graft Versus Host Disease in Patients Undergoing Allogeneic Hematopoietic Cell Transplantation After Reduced Intensity Conditioning Single-country: United States (1 site) Decision brief → | Ph2 | City of Hope Medical Center | recruiting | 2025-02-07 | 2028-10-15 |
| BMT-13 · NCT06802315 Intensity Modulated Total Marrow Irradiation in Fully Human Leukocyte Antigen (HLA)-Matched and Partially-HLA Mismatched Allogeneic Transplantation Patients With High-Risk Acute Myeloid Leukemia (AML), Chronic Myeloid Leukemia (CML), and Myelodysplastic Syndrome (MDS) Single-country: United States (1 site) Decision brief → | Ph2 | University of Illinois Chicago | recruiting | 2025-01-31 | 2030-03 |
| TECTONIC · NCT06691217 Effects of IL-1 Beta Inhibition on Vascular Inflammation in TET2 Clonal Hematopoiesis Single-country: United States (1 site) Decision brief → | Ph2 | Massachusetts General Hospital | recruiting | 2024-11-15 | 2029-01-01 |
| NCT06680661 ABBA CORD: dCBT w/ Abatacept for aGVHD Prophylaxis Single-country: United States (1 site) Decision brief → | Ph2 | Leland Metheny | suspended | 2024-11-08 | 2027-10-29 |
| NCT06629584 Phase II Study of Asciminib for Second-line Treatment of Chronic Phase Chronic Myeloid Leukemia Single-country: United States (1 site) Decision brief → | Ph2 | M.D. Anderson Cancer Center | recruiting | 2024-10-08 | 2026-12-31 |
| NCT06630221 Eltrombopag as a Novel Therapeutic Approach for Low-risk MDS and CMML With TET2 Mutations Single-country: United States (1 site) Decision brief → | Ph2 | Abhay Singh, MD MPH | suspended | 2024-10-08 | 2028-01-01 |
| NCT06597734 A Phase 2 Study Evaluating Olutasidenib in Combination With Hypomethylating Agents in Patients With IDH1-mutated Higher-risk Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia, or Advanced Myeloproliferative Neoplasm No sites listed Decision brief → | Ph2 | M.D. Anderson Cancer Center | withdrawn | 2024-09-19 | 2026-06-11 |
| NCT06566742 A Phase 2 Study Evaluating Olutasidenib in Patients With IDH1-mutated Clonal Cytopenia of Undetermined Significance and Lower-risk Myelodysplastic/Syndromes/Chronic Myelomonocytic Leukemia. Single-country: United States (2 sites) Decision brief → | Ph2 | M.D. Anderson Cancer Center | recruiting | 2024-08-22 | 2027-08-31 |
| NCT06563804 A Study to Evaluate S227928 as a Single Agent and in Combination With Venetoclax in Patients With R/R AML, MDS/AML, or CMML 6 countries, 31% of sites in the US Decision brief → | Ph1/Ph2 | Servier Bio-Innovation LLC | terminated | 2024-08-21 | 2025-10-09 |
| NCT06523556 Axatilimab With or Without Azacitidine for the Treatment of Patients With Advanced Phase Myeloproliferative Neoplasms, Myeloproliferative Neoplasm/Myelodysplastic Syndrome Overlap or High Risk Chronic Myelomonocytic Leukemia Single-country: United States (2 sites) Decision brief → | Ph1/Ph2 | Uma Borate | recruiting | 2024-07-26 | 2027-10-31 |
| ASC4TARGET · NCT06514534 Open-label Study of Asciminib for CML-CP or CML-AP Patients With T315I Mutation Who Are Resistant, Intolerant or Ineligible to Ponatinib. Single-country: France (6 sites) Decision brief → | Ph2 | Novartis Pharmaceuticals | recruiting | 2024-07-23 | 2029-02-17 |
| AsterA · NCT06368414 A Study of Treatment-free Remission in Chronic Phase Chronic Myeloid Leukemia Single-country: South Korea (1 site) Decision brief → | Ph2 | Korean Society of Hematology | recruiting | 2024-04-16 | 2028-08-31 |
| NCT06236724 Phase II Study Assessing Efficacy and Safety of Asciminib in Patients With Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase. Single-country: United States (1 site) Decision brief → | Ph2 | M.D. Anderson Cancer Center | recruiting | 2024-02-01 | 2033-07-01 |
| CARDINAL · NCT06163430 A Clinical Study of MK-4208/TERN-701 in Participants With Chronic Myeloid Leukemia (CML) (MK-4208-003/Tern701-1012/CARDINAL) 9 countries, 33% of sites in the US Decision brief → | Ph1/Ph2 | Terns, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) | recruiting | 2023-12-08 | 2029-11-30 |
| NCT06159491 Pacritinib in CMML Single-country: United States (1 site) Decision brief → | Ph1/Ph2 | Douglas Tremblay | recruiting | 2023-12-06 | 2027-07 |
| NCT06059391 CMV-MVA Triplex Vaccination in HLA-Matched Related Stem Cell Donors for the Prevention of CMV Infection in Patients Undergoing Hematopoietic Stem Cell Transplant Single-country: United States (3 sites) Decision brief → | Ph2 | City of Hope Medical Center | recruiting | 2023-09-28 | 2027-01-01 |
| NCT06013423 Cord Blood Transplant, Cyclophosphamide, Fludarabine, and Total-Body Irradiation in Treating Patients With High-Risk Hematologic Diseases Single-country: United States (1 site) Decision brief → | Ph2 | Fred Hutchinson Cancer Center | recruiting | 2023-08-28 | 2031-10-31 |
| OPTIMIZE · NCT06001385 HLA-Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation With Reduced Dose Post Transplantation Cyclophosphamide GvHD Prophylaxis Single-country: United States (32 sites) Decision brief → | Ph2 | Center for International Blood and Marrow Transplant Research | active not recruiting | 2023-08-21 | 2026-12-24 |
| NCT05884333 Cord Blood Transplant in Adults With Blood Cancers Single-country: United States (1 site) Decision brief → | Ph2 | Memorial Sloan Kettering Cancer Center | active not recruiting | 2023-06-01 | 2028-05-22 |
| NCT05807932 Venetoclax in Addition to Sequential Conditioning With Fludarabine / Amsacrine / Ara-C (FLAMSA) + Treosulfan for Allogeneic Blood Stem Cell Transplantation in Patients With MDS, CMML or sAML Single-country: Germany (6 sites) Decision brief → | Ph1/Ph2 | Heinrich-Heine University, Duesseldorf | recruiting | 2023-04-11 | 2029-04-30 |
| NCT05805605 Allo HSCT Using RIC and PTCy for Hematological Diseases Single-country: United States (1 site) Decision brief → | Ph2 | Masonic Cancer Center, University of Minnesota | recruiting | 2023-04-10 | 2027-10-22 |
| NCT05800210 Alpha/Beta T Cell and CD19+ B Cell Depletion in Allogeneic Stem Cell Transplantation in Patients With Malignant Diseases Single-country: United States (1 site) Decision brief → | Ph2 | University of Florida | recruiting | 2023-04-05 | 2027-05 |
| AVENHIR · NCT05768711 Azacitidine Combined With Venetoclax in Patients With Higher-risk Chronic Myelomonocytic Leukemia (AVENHIR) Single-country: France (24 sites) Decision brief → | Ph2 | Groupe Francophone des Myelodysplasies | active not recruiting | 2023-03-14 | 2026-06-16 |
| VARIANT · NCT05701215 Venetoclax After TKI to Target Persisting Stem Cells in CML Single-country: Germany (2 sites) Decision brief → | Ph2 | Thomas Ernst, PD Dr. med. | completed | 2023-01-27 | 2026-05-31 |
| NCT05656248 Study of CPX-351 (VYXEOS) in Individuals < 22 Years With Secondary Myeloid Neoplasms Single-country: United States (1 site) Decision brief → | Ph2 | St. Jude Children's Research Hospital | active not recruiting | 2022-12-19 | 2025-08-28 |
| NCT05600894 Venetoclax in Combination With ASTX727 for the Treatment of Chronic Myelomonocytic Leukemia and Other Myelodysplastic Syndrome/Myeloproliferative Neoplasm 2 countries, 97% of sites in the US Decision brief → | Ph2 | National Cancer Institute (NCI) | active not recruiting | 2022-11-01 | 2027-08-31 |
| NCT05589896 A First-in-Human Study of HLA-Partially to Fully Matched Allogenic Cryopreserved Deceased Donor Bone Marrow Transplantation for Patients With Hematologic Malignancies Single-country: United States (9 sites) Decision brief → | Ph1/Ph2 | Ossium Health, Inc. | active not recruiting | 2022-10-21 | 2026-07-14 |
| BEXMAB · NCT05428969 A Study to Assess Safety, Tolerability and Preliminary Efficacy of Bexmarilimab in Combination With Standard of Care in Patients With Hematological Malignancies 3 countries, 40% of sites in the US Decision brief → | Ph1/Ph2 | Faron Pharmaceuticals Ltd | active not recruiting | 2022-06-23 | 2027-03 |
| ASC2ESCALATE · NCT05384587 Asciminib Monotherapy, With Dose Escalation, for 2nd and 1st Line Chronic Myelogenous Leukemia Single-country: United States (80 sites) Decision brief → | Ph2 | Novartis Pharmaceuticals | active not recruiting | 2022-05-20 | 2025-08-13 |
| NCT05364762 Adding Itacitinib to Cyclophosphamide and Tacrolimus for the Prevention of Graft Versus Host Disease in Patients Undergoing Hematopoietic Stem Cell Transplants Single-country: United States (1 site) Decision brief → | Ph2 | City of Hope Medical Center | active not recruiting | 2022-05-06 | 2027-03-25 |
| NCT05322850 Phase I/II Trial: Engineered Donor Graft (Orca Q) for Pediatric Hematopoietic Cell Transplant (HCT) Single-country: United States (4 sites) Decision brief → | Ph1/Ph2 | University of Florida | recruiting | 2022-04-12 | 2027-09 |
| NCT05282459 Enasidenib in MDS &Non-proliferative Chronic Myelomonocytic Leukemia w/o IDH2 Mutation Single-country: United States (1 site) Decision brief → | Ph1/Ph2 | Tian Yi Zhang | completed | 2022-03-16 | 2024-12-03 |
| NCT05201066 Roll-over Study for Patients Who Have Completed a Prior Novartis-sponsored Sabatolimab (MBG453) Study and Are Judged by the Investigator to Benefit From Continued Treatment With Sabatolimab. 15 countries, 8% of sites in the US Decision brief → | Ph2 | Novartis Pharmaceuticals | active not recruiting | 2022-01-21 | 2028-02-14 |
| NCT05184842 Metabolically Optimized, Non-cytotoxic Low Dose Weekly Decitabine/Venetoclax in MDS and AML Single-country: United States (3 sites) Decision brief → | Ph2 | Montefiore Medical Center | recruiting | 2022-01-11 | 2023-12-20 |
| ALERTCML · NCT05143840 Asciminib as Initial Therapy for Patients With Chronic Myeloid Leukemia in Chronic Phase Single-country: United States (8 sites) Decision brief → | Ph2 | University of Alabama at Birmingham | active not recruiting | 2021-12-03 | 2032-02 |
| NCT05115630 Off-the-shelf NK Cells + SCT for Myeloid Malignancies Single-country: United States (1 site) Decision brief → | Ph2 | M.D. Anderson Cancer Center | completed | 2021-11-10 | 2025-05-15 |
| NCT05092451 Phase I/II Study of CAR.70- Engineered IL15-transduced Cord Blood-derived NK Cells in Conjunction With Lymphodepleting Chemotherapy for the Management of Relapse/Refractory Hematological Malignances Single-country: United States (1 site) Decision brief → | Ph1/Ph2 | M.D. Anderson Cancer Center | recruiting | 2021-10-25 | 2030-08-31 |
| NCT05038592 Phase I/II Study of Tagraxofusp in Combination With Decitabine for Patients With Myelomonocytic/Myeloproliferative Neoplasm and High Risk Myelodysplastic Syndromes Single-country: United States (1 site) Decision brief → | Ph1/Ph2 | M.D. Anderson Cancer Center | active not recruiting | 2021-09-09 | 2027-01-29 |
| NCT05031897 Two Step Haplo With Radiation Conditioning Single-country: United States (1 site) Decision brief → | Ph2 | Thomas Jefferson University | recruiting | 2021-09-02 | 2032-04 |
| NCT05024994 A Study of E7820 in People With Bone Marrow (Myeloid) Cancers Single-country: United States (7 sites) Decision brief → | Ph2 | Memorial Sloan Kettering Cancer Center | completed | 2021-08-27 | 2025-06-19 |
| NCT05007873 ASTX727 and Dasatinib for the Treatment of Newly Diagnosed Philadelphia Chromosome or BCR-ABL Positive Chronic Myeloid Leukemia in Chronic Phase Single-country: United States (1 site) Decision brief → | Ph2 | M.D. Anderson Cancer Center | active not recruiting | 2021-08-17 | 2028-10-30 |
| NCT04996875 (Apex) Bezuclastinib in Patients With Advanced Systemic Mastocytosis 14 countries, 33% of sites in the US Decision brief → | Ph2 | Cogent Biosciences, Inc. | recruiting | 2021-08-09 | 2025-09-19 |
| NCT04925479 Study to Determine the Dose and Safety of Asciminib in Pediatric Patients With Chronic Myeloid Leukemia 12 countries, 13% of sites in the US Decision brief → | Ph1/Ph2 | Novartis Pharmaceuticals | active not recruiting | 2021-06-14 | 2027-09-03 |
| ACCESS · NCT04904588 HLA-Mismatched Unrelated Donor Hematopoietic Cell Transplantation With Post-Transplantation Cyclophosphamide Single-country: United States (39 sites) Decision brief → | Ph2 | Center for International Blood and Marrow Transplant Research | active not recruiting | 2021-05-27 | 2026-08 |
| MoTD · NCT04888741 Methods of T Cell Depletion Trial (MoTD) Single-country: United Kingdom (17 sites) Decision brief → | Ph2 | University of Birmingham | recruiting | 2021-05-17 | 2027-08-23 |
| NCT04838041 Protocol Number: HJKC3-0003. Treatment Free Remission After Asciminib Based Therapy in Chronic Phase Chronic Myeloid Leukemia (CP-CML) Patients Who Relapsed After a Prior Attempt at TKI Discontinuation Single-country: United States (5 sites) Decision brief → | Ph2 | Medical College of Wisconsin | recruiting | 2021-04-08 | 2028-06 |
| NCT04802161 Comparing the Addition of an Anti-Cancer Drug, Pomalidomide, to the Usual Chemotherapy Treatment (Daunorubicin and Cytarabine Liposome) in Newly Diagnosed Acute Myeloid Leukemia With Myelodysplastic Syndrome-Related Changes Single-country: United States (11 sites) Decision brief → | Ph2 | National Cancer Institute (NCI) | active not recruiting | 2021-03-17 | 2024-11-21 |
| NCT04761770 Study of a Geriatric Assessment to Plan a Treatment Approach for Older People With Various Blood Disorders Single-country: United States (7 sites) Decision brief → | Ph2 | Memorial Sloan Kettering Cancer Center | active not recruiting | 2021-02-21 | 2027-02 |
| NCT04734990 Seclidemstat and Azacitidine for the Treatment of Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia Single-country: United States (1 site) Decision brief → | Ph1/Ph2 | M.D. Anderson Cancer Center | active not recruiting | 2021-02-02 | 2027-09-11 |
| NCT04655755 Venetoclax in Combination With ASTX727 for the Treatment of Treatment-Naive High-Risk Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia Single-country: United States (1 site) Decision brief → | Ph1/Ph2 | M.D. Anderson Cancer Center | active not recruiting | 2020-12-07 | 2028-07-20 |
| TOKIN · NCT04626024 Safety And Efficacy Of TKI Cessation For CML Patients With Stable Molecular Response In A Real World Population Single-country: United States (4 sites) Decision brief → | Ph2 | Baylor College of Medicine | active not recruiting | 2020-11-12 | 2028-11-15 |
| NCT04588922 Study of SLS009 (Formerly GFH009) a Potent Highly Selective CDK9 Inhibitor in Patients With Hematologic Malignancies and High-Risk Newly Diagnosed AML 2 countries, 59% of sites in the US Decision brief → | Ph1/Ph2 | Sellas Life Sciences Group | recruiting | 2020-10-19 | 2026-12-30 |
| NCT04581512 Study to Evaluate the Safety and Tolerability of EP0042 3 countries, 0% of sites in the US Decision brief → | Ph1/Ph2 | Ellipses Pharma | recruiting | 2020-10-09 | 2027-12 |
| NCT04550442 Venetoclax and Azacitidine for the Treatment of Relapsed or Refractory High-Risk Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia Single-country: United States (1 site) Decision brief → | Ph1/Ph2 | M.D. Anderson Cancer Center | terminated | 2020-09-16 | 2026-05-29 |
| NCT04493138 Azacitidine and Quizartinib for the Treatment of Myelodysplastic Syndrome or Myelodysplastic/Myeloproliferative Neoplasm With FLT3 or CBL Mutations Single-country: United States (1 site) Decision brief → | Ph1/Ph2 | M.D. Anderson Cancer Center | active not recruiting | 2020-07-30 | 2027-12-31 |
| CONCERTO · NCT04409639 Cobimetinib in Newly Diagnosed or HMA-treated CMML Patients With RAS Pathway Mutations Single-country: United States (3 sites) Decision brief → | Ph2 | University of Utah | active not recruiting | 2020-06-01 | 2026-01-02 |
| NCT04258943 Bosutinib in Pediatric Patients With Newly Diagnosed Chronic Phase or Resistant/Intolerant Ph + Chronic Myeloid Leukemia 8 countries, 76% of sites in the US Decision brief → | Ph1/Ph2 | Children's Oncology Group | active not recruiting | 2020-02-06 | 2028-07 |
| NCT04239157 A Phase II, Open-Label, Study of Subcutaneous Canakinumab, an Anti-IL-1β Human Monoclonal Antibody, for Patients With Low or Int-1 Risk IPSS/IPSS-R Myelodysplastic Syndromes and Chronic Myelomonocytic Leukemia Single-country: United States (1 site) Decision brief → | Ph2 | M.D. Anderson Cancer Center | recruiting | 2020-01-23 | 2026-12-31 |
| NCT04233346 The Study for CML Who Failed Prior TKIs or With T315I Mutation or Ph+ ALL Who Failed Prior TKIs or With T315I Mutation Single-country: China (14 sites) Decision brief → | Ph2 | Otsuka Beijing Research Institute | completed | 2020-01-18 | 2022-07-22 |
| NCT04216563 ABL001 for the Treatment of Chronic Myeloid Leukemia in Patients Who Are on Therapy With Tyrosine Kinase Inhibitor Single-country: United States (1 site) Decision brief → | Ph2 | M.D. Anderson Cancer Center | terminated | 2020-01-02 | 2025-03-17 |
| NCT04195633 Donor Stem Cell Transplant With Treosulfan, Fludarabine, and Total-Body Irradiation for the Treatment of Hematological Malignancies Single-country: United States (1 site) Decision brief → | Ph2 | Fred Hutchinson Cancer Center | recruiting | 2019-12-12 | 2027-04-15 |
| NCT04191187 Reduced Intensity Flu/Mel/TBI Conditioning for HAPLO HCT Patients With Hematologic Malignancies Single-country: United States (1 site) Decision brief → | Ph2 | H. Lee Moffitt Cancer Center and Research Institute | completed | 2019-12-09 | 2024-02-11 |
| NCT04188405 Decitabine, Venetoclax, and Ponatinib for the Treatment of Philadelphia Chromosome-Positive Acute Myeloid Leukemia or Myeloid Blast Phase or Accelerated Phase Chronic Myelogenous Leukemia Single-country: United States (1 site) Decision brief → | Ph2 | M.D. Anderson Cancer Center | completed | 2019-12-05 | 2026-06-02 |
| ResToP · NCT04160546 Study to Evaluate the Reinduction and Second Stop of TKI With Ponatinib in CML in Molecular Response (ResToP) Single-country: Spain (13 sites) Decision brief → | Ph2 | Fundacion CRIS de Investigación para Vencer el Cáncer | completed | 2019-11-13 | 2025-12-31 |
| NCT04160052 Venetoclax and Azacitidine for the Treatment of High-Risk Recurrent or Refractory Myelodysplastic Syndrome Single-country: United States (1 site) Decision brief → | Ph1/Ph2 | M.D. Anderson Cancer Center | terminated | 2019-11-12 | 2026-02-03 |
| NCT04140487 Azacitidine, Venetoclax, and Gilteritinib in Treating Patients With Recurrent/Refractory FLT3-Mutated Acute Myeloid Leukemia, Chronic Myelomonocytic Leukemia, or High-Risk Myelodysplastic Syndrome/Myeloproliferative Neoplasm Single-country: United States (1 site) Decision brief → | Ph1/Ph2 | M.D. Anderson Cancer Center | recruiting | 2019-10-28 | 2028-09-01 |
| NCT04093570 A Study for Participants Who Participated in Prior Clinical Studies of ASTX727 (Standard Dose) 13 countries, 45% of sites in the US Decision brief → | Ph2 | Taiho Oncology, Inc. | enrolling by invitation | 2019-09-18 | 2027-12-31 |
| TIPI · NCT04070443 Safety and Efficacy of Ponatinib Followed by Imatinib in Patients With Chronic Myelogenous Leukemia in Chronic Phase Single-country: France (28 sites) Decision brief → | Ph2 | Centre Leon Berard | active not recruiting | 2019-08-28 | 2029-06-01 |
| NCT04060277 Triplex Vaccine in Preventing CMV Infection in Patients Undergoing Hematopoietic Stem Cell Transplantation Single-country: United States (1 site) Decision brief → | Ph2 | City of Hope Medical Center | active not recruiting | 2019-08-19 | 2023-06-06 |
| NCT03934372 Safety and Efficacy of Ponatinib for Treatment of Pediatric Recurrent or Refractory Leukemias, Lymphomas or Solid Tumors 7 countries, 0% of sites in the US Decision brief → | Ph1/Ph2 | Incyte Biosciences International Sàrl | recruiting | 2019-05-01 | 2028-02-01 |
| NCT03922100 Study of NMS-03592088 in Patients With Relapsed or Refractory AML or CMML 3 countries, 0% of sites in the US Decision brief → | Ph1/Ph2 | Nerviano Medical Sciences | terminated | 2019-04-19 | 2024-08-29 |
| CMLXI · NCT03906292 Frontline Asciminib Combination in Chronic Phase CML Single-country: Germany (21 sites) Decision brief → | Ph2 | University of Jena | active not recruiting | 2019-04-08 | 2027-03 |
| PONAZA · NCT03895671 PONAZA : A COMBINATION OF PONATINIB AND 5-AZACITIDINE IN CHRONIC MYELOGENOUS LEUKAEMIA IN ACCELERATED PHASE OR IN MYELOID BLAST CRISIS Single-country: France (29 sites) Decision brief → | Ph2 | Versailles Hospital | completed | 2019-03-29 | 2025-08-31 |
| DANTE · NCT03874858 A Study of Full Treatment-free Remission in Patients With Chronic Myeloid Leukemia Single-country: Italy (26 sites) Decision brief → | Ph2 | Novartis Pharmaceuticals | terminated | 2019-03-14 | 2025-10-15 |
| NCT03862157 Azacitidine, Venetoclax, and Pevonedistat in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia Single-country: United States (1 site) Decision brief → | Ph1/Ph2 | M.D. Anderson Cancer Center | active not recruiting | 2019-03-05 | 2027-01-31 |
| TUSCANY · NCT03850574 Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Tuspetinib (HM43239) in Patients With Relapsed or Refractory Acute Myeloid Leukemia 6 countries, 44% of sites in the US Decision brief → | Ph1/Ph2 | Aptose Biosciences Inc. | recruiting | 2019-02-22 | 2026-11 |
| NCT03849651 TCRαβ-depleted Progenitor Cell Graft With Additional Memory T-cell DLI, Plus Selected Use of Blinatumomab, in Naive T-cell Depleted Haploidentical Donor Hematopoietc Cell Transplantation for Hematologic Malignancies Single-country: United States (1 site) Decision brief → | Ph2 | St. Jude Children's Research Hospital | active not recruiting | 2019-02-21 | 2024-08-07 |
| NCT03842696 Vorinostat for Graft vs Host Disease Prevention in Children, Adolescents and Young Adults Undergoing Allogeneic Blood and Marrow Transplantation Single-country: United States (7 sites) Decision brief → | Ph1/Ph2 | University of Michigan Rogel Cancer Center | active not recruiting | 2019-02-15 | 2025-07-30 |
| NCT03817398 Stopping Tyrosine Kinase Inhibitors in Affecting Treatment-Free Remission in Patients With Chronic Phase Chronic Myeloid Leukemia 4 countries, 91% of sites in the US Decision brief → | Ph2 | Children's Oncology Group | active not recruiting | 2019-01-25 | 2026-09-30 |
| NCT03779854 Naive T Cell Depletion for Preventing Chronic Graft-versus-Host Disease in Children and Young Adults With Blood Cancers Undergoing Donor Stem Cell Transplant Single-country: United States (9 sites) Decision brief → | Ph2 | Fred Hutchinson Cancer Center | active not recruiting | 2018-12-19 | 2027-08-31 |
| NCT03722407 Ruxolitinib for the Treatment of Chronic Myelomonocytic Leukemia (CMML): A Phase 2 Expansion Single-country: United States (5 sites) Decision brief → | Ph2 | H. Lee Moffitt Cancer Center and Research Institute | active not recruiting | 2018-10-29 | 2022-09-19 |
| NCT03683433 Enasidenib and Azacitidine in Treating Patients With Recurrent or Refractory Acute Myeloid Leukemia and IDH2 Gene Mutation Single-country: United States (1 site) Decision brief → | Ph2 | M.D. Anderson Cancer Center | recruiting | 2018-09-25 | 2027-09-20 |
| NCT03674411 Trial Evaluating MGTA-456 in Patients With High-Risk Malignancy Single-country: United States (1 site) Decision brief → | Ph2 | Masonic Cancer Center, University of Minnesota | active not recruiting | 2018-09-17 | 2020-06-23 |
| NCT03672539 Liposome-encapsulated Daunorubicin-Cytarabine and Gemtuzumab Ozogamicin in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) or High Risk Myelodysplastic Syndrome Single-country: United States (1 site) Decision brief → | Ph2 | M.D. Anderson Cancer Center | completed | 2018-09-14 | 2026-07-17 |
| NCT03670966 211At-BC8-B10 Followed by Donor Stem Cell Transplant in Treating Patients With Relapsed or Refractory High-Risk Acute Leukemia or Myelodysplastic Syndrome Single-country: United States (1 site) Decision brief → | Ph1/Ph2 | Fred Hutchinson Cancer Center | recruiting | 2018-09-14 | 2028-01-28 |
| NCT03654768 Testing the Addition of Ruxolitinib to the Usual Treatment (Tyrosine Kinase Inhibitors) for Chronic Myeloid Leukemia Single-country: United States (541 sites) Decision brief → | Ph2 | SWOG Cancer Research Network | active not recruiting | 2018-08-31 | 2024-07-01 |
| NCT03622788 Cytokine-Treated Veto Cells in Treating Patients With Hematologic Malignancies Following Stem Cell Transplant Single-country: United States (1 site) Decision brief → | Ph1/Ph2 | M.D. Anderson Cancer Center | active not recruiting | 2018-08-09 | 2027-12-01 |
| NCT03610971 Treatment Free Remission After Combination Therapy With Ruxolitinib Plus Tyrosine Kinase Inhibitors Single-country: United States (8 sites) Decision brief → | Ph2 | H. Lee Moffitt Cancer Center and Research Institute | active not recruiting | 2018-08-01 | 2025-09-25 |
| NCT03589729 Dexrazoxane Hydrochloride in Preventing Heart-Related Side Effects of Chemotherapy in Participants With Blood Cancers Single-country: United States (1 site) Decision brief → | Ph2 | M.D. Anderson Cancer Center | recruiting | 2018-07-18 | 2027-12-31 |
| NCT03588078 Study of the Safety and Efficacy of APR-246 in Combination With Azacitidine Single-country: France (7 sites) Decision brief → | Ph1/Ph2 | Groupe Francophone des Myelodysplasies | completed | 2018-07-17 | 2020-05-01 |
| NCT03578367 Study of Efficacy and Safety of Asciminib in Combination With Imatinib in Patients With Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Who Have Been Previously Treated With Imatinib and Have Not Achieved Deep Molecular Response. 15 countries, 7% of sites in the US Decision brief → | Ph2 | Novartis Pharmaceuticals | completed | 2018-07-06 | 2021-11-08 |
| NCT03516279 Pembrolizumab and Dasatinib, Imatinib Mesylate, or Nilotinib in Treating Patients With Chronic Myeloid Leukemia and Persistently Detectable Minimal Residual Disease Single-country: United States (291 sites) Decision brief → | Ph2 | ECOG-ACRIN Cancer Research Group | active not recruiting | 2018-05-04 | 2028-08-31 |
| NCT03418038 Ascorbic Acid and Chemotherapy for the Treatment of Relapsed or Refractory Lymphoma, CCUS, and Chronic Myelomonocytic Leukemia Single-country: United States (4 sites) Decision brief → | Ph2 | Mayo Clinic | recruiting | 2018-02-01 | 2031-02-22 |
| NCT03404193 Venetoclax and Decitabine in Treating Participants With Relapsed/Refractory Acute Myeloid Leukemia or Relapsed High-Risk Myelodysplastic Syndrome Single-country: United States (1 site) Decision brief → | Ph2 | M.D. Anderson Cancer Center | terminated | 2018-01-19 | 2026-03-05 |
| NCT03399773 Infusion of Expanded Cord Blood Cells in Addition to Single Cord Blood Transplant in Treating Patients With Acute Leukemia, Chronic Myeloid Leukemia, or Myelodysplastic Syndromes Single-country: United States (1 site) Decision brief → | Ph2 | Fred Hutchinson Cancer Center | active not recruiting | 2018-01-16 | 2025-06-09 |
| NCT03383575 Azacitidine and Enasidenib in Treating Patients With IDH2-Mutant Myelodysplastic Syndrome Single-country: United States (3 sites) Decision brief → | Ph2 | M.D. Anderson Cancer Center | recruiting | 2017-12-26 | 2027-02-28 |
| NCT03314974 Myeloablative Allo HSCT With Related or Unrelated Donor for Heme Disorders Single-country: United States (1 site) Decision brief → | Ph2 | Masonic Cancer Center, University of Minnesota | recruiting | 2017-10-19 | 2027-06-10 |
| NCT03289910 Topotecan Hydrochloride and Carboplatin With or Without Veliparib in Treating Advanced Myeloproliferative Disorders and Acute Myeloid Leukemia or Chronic Myelomonocytic Leukemia Single-country: United States (6 sites) Decision brief → | Ph2 | National Cancer Institute (NCI) | active not recruiting | 2017-09-21 | 2023-05-31 |
| NCT03263572 Blinatumomab, Methotrexate, Cytarabine, and Ponatinib in Treating Patients With Philadelphia Chromosome-Positive, or BCR-ABL Positive, or Relapsed/Refractory, Acute Lymphoblastic Leukemia Single-country: United States (1 site) Decision brief → | Ph2 | M.D. Anderson Cancer Center | recruiting | 2017-08-28 | 2027-11-30 |
| NCT03246906 Comparison of Triple GVHD Prophylaxis Regimens for Nonmyeloablative or Reduced Intensity Conditioning Unrelated Mobilized Blood Cell Transplantation Single-country: United States (1 site) Decision brief → | Ph2 | Fred Hutchinson Cancer Center | terminated | 2017-08-11 | 2025-05-03 |
| NCT03192397 Chemotherapy, Total Body Irradiation, and Post-Transplant Cyclophosphamide in Reducing Rates of Graft Versus Host Disease in Patients With Hematologic Malignancies Undergoing Donor Stem Cell Transplant Single-country: United States (1 site) Decision brief → | Ph1/Ph2 | Roswell Park Cancer Institute | active not recruiting | 2017-06-20 | 2023-08-21 |
| NCT03147612 Low-Intensity Chemotherapy, Ponatinib and Blinatumomab in Treating Patients With Philadelphia Chromosome-Positive and/or BCR-ABL Positive Acute Lymphoblastic Leukemia Single-country: United States (1 site) Decision brief → | Ph2 | M.D. Anderson Cancer Center | active not recruiting | 2017-05-10 | 2027-02-28 |